



The official Newsletter of the

# VITREO RETINAL SOCIETY - INDIA

Official Website : [www.vrsi.in](http://www.vrsi.in)

January - April 2013



**Dr Mangat R Dogra**  
President - VRSI

## From the President's Desk

Dear Friends

At the outset, I would like to thank all members of Vitreo Retinal Society- India (VRSI) for electing me as a President of this prestigious society for next two years. I express my gratitude to my illustrious predecessor Dr Gopal Lal Verma for taking this society to greater heights. He was instrumental in organising a very successful Asia Pacific Vitreo Retinal Society Congress with VRSI at Hyderabad in December, 2011. He has set a very high benchmark for me to follow. With your blessings, I will try my best to bring all vitreoretinal specialists of this country under the umbrella of this society and raise its stature further.

On behalf of VRSI members, I would like to thank and put on records the efforts of Dr S Natarajan who brought out regularly excellent issues of VRSI news letter since 2008. There is change in editorial team after almost five years. Dr V Narendran Convener Scientific Committee VRSI has taken over this task and is going to bring out this and future issues of VRSI news letter. This issue highlights some aspects of last VRSI conference held at Guwahati in December, 2012. It also announces the next VRSI conference to be held between 12<sup>th</sup> to 14<sup>th</sup>, December, 2013 at Lavasa International Convention Centre which is close to Pune.

Main article in this issue is on "OCT imaging through gas for post-operative protocol of macular hole" which has been contributed by Dr Taji Sakamoto, professor of ophthalmology at Kagshima University, Japan. He was an invited speaker during the last VRSI conference at Guwahati. The other two articles on "navigated laser photocoagulation system (NAVILAS)" and "Treatment Options for Myopic foveoschisis-an update" are contributed by Dr Jay Chablani VR consultant at L V Prasad Eye Institute Hyderabad and Dr Pramod Bhende from Shankara Nethralaya, Chennai respectively.

VRSI has taken a lead to collaborate with other national and international societies. VRSI has been invited by the European Society of Retina Specialists (EURETINA) to organise a symposium during the next Annual EURETINA Congress to be held from 26<sup>th</sup> to 28<sup>th</sup>, September, 2013 at Hamburg, Germany. We are also invited by Uveitis Society of India (USI) to organise a symposium on behalf of VRSI during their Annual Conference to be held at Mussoorie, on 27<sup>th</sup> and 28<sup>th</sup>, September, 2013. This is reciprocal arrangement with Uveitis Society of India. They will organise a symposium on uveitis during the next VRSI conference at Lavasa. This year, Nataraja Pillai Award will be bestowed on Prof. Alan Bird emeritus Professor at Moorfield Eye Hospital London. We are delighted to nominate Prof. R V Azad Chief Dr P R Centre (AIIMS) New Delhi for VRSI B. Patnaik Award. Both invitees would deliver their award lecture at the next VRSI conference at Lavasa.

I would like to thank editorial team lead by Dr V Narendran and all contributors of this issue. I hope you will find current issue of news letter enriching and useful. I hope that VRSI news letter would bring out latest information in simplified manner for benefit of all VRSI members.

With best wishes

**Dr Mangat R Dogra**

President Vitreo Retinal Society-India

Professor of Ophthalmology, Advanced Eye Centre

PGIMER, Chandigarh 160012



**Dr. A Giridhar**  
Honorary Secretary

## From the Honorary Secretary's Desk

### Honorary Secretary's Message for the 1st Issue of VRS-I newsletter for the year 2013

Dear Colleagues,

Warm greetings from the Governing Council of the Vitreo Retinal Society-India!

This is the first Newsletter for the year 2013 being brought out by a team of new office bearers under the Chairmanship of Dr V Narendran. I hope you will find it interesting.

The annual meeting of the Vitreo Retinal Society-India held at Guwahati was a great success; thanks for the sincere efforts of Dr Harsha Bhattacharjee, Dr Satyen Deka and a team of Doctors from Sankaradeva Nethralaya. We had a very good attendance and the scientific program prepared by Dr NS Muralidhar was appreciated by everyone.

We are now in the process of coordinating the arrangements for the next annual meeting of the VRS-I to be held at Lavassa International Convention Centre, near Pune. We had inspected the venue last month and we felt that this is an excellent place to have the conference and also to relax in the week end. Members can therefore plan to come with their families and I am sure that you will have a wonderful time.

I would like to congratulate two of our members viz. Dr S. Natarajan and Dr Tara Prasad Das who were conferred with the Padmashree by the President of India in the year 2013. Congratulations to Dr Alay Banker from Ahmedabad who received the prestigious Col. Rangachari Medal for the best paper presented at the last APAO-AIOS held at Hyderabad.

One CME was held under the aegis of VRS-I this year at Armed Forces Medical College, Pune and we are looking forward to more applications for conducting similar CMEs by our members elsewhere in the country.

With best wishes!

**Dr. A Giridhar**

Honorary Secretary



**Dr. V. Narendran**  
Convener Scientific Committee  
VRS-I

## From the Convener Scientific Committee Desk

Dear Colleagues,

At the outset I'll like to thank the Governing Council of VRS-I for electing me the Convener Scientific Committee. With the active and enthusiastic cooperation of my colleagues carrying forward the good work of my predecessor Dr. Muralidhar should be easy.

We are happy to announce the 22nd Annual VRS-I Conference, to be held between 12 to 14 December, in Lavasa near Pune. The abstract submission website is [www.vrsi.co.in](http://www.vrsi.co.in) and submission begins from 1st May 2013 till 31st July 2013. I encourage to all the VRS-I members (especially the youngsters) to submit their abstracts and welcome one and all to this picturesque town of Lavasa.

Congratulations to Dr. S. Natarajan and Dr. Taraprasad Das for receiving the prestigious Padmashri Award from the President of India.

The editorial board has as usual come up with an interesting selection of topics for everyone.

Warm regards,

**Dr. V. Narendran**

Convener Scientific Committee,  
VRS-I.


**Vitreo Retinal Society of India congratulates Dr. S. Natarajan & Dr. Taraprasad Das for being conferred Padmashri Award 2013 by the President of India.**



**Dr. S. Natarajan**



**Dr. Taraprasad Das**



**Dr. Taiji Sakamoto,**  
**MD, PhD**

## OCT imaging through gas for post-operative protocol of macular hole

Current maculae hole (MH) surgery consists of pars planavitrectomy, eliminating all traction around the hole, gas tamponade and posturing, which has increased the closure rate to approximately 90%. Recently, no posturing or short posturing is becoming a trend of post-operative protocol. Despite these improvements, there are still concerns that a shorter duration of posturing might lead to failure in some eyes. In order to maximize the success rate of MH closure rate while minimizing patients' burden, an individualized post-operative program would be much more desirable than the uniform program. The key to an individualized posturing regimen is an early evaluation of MHs status during the gas-filled period after surgery (gas-OCT). We have previously reported the reliability of SD-OCT evaluation in a gas-filled eye for MH closure evaluation.<sup>1,2</sup> In my lecture at Guwahati in December 2012, I introduced some techniques of this protocol and showed some cases. The first case was 68 yo female with stage 3 MH (Fig 1A). After the regular vitrectomy, SD-OCT was performed through a gas. Using an old method, macular area was not clearly seen (Fig 1B), however, the new method showed MH closed on day 1 (Fig 1C). The second case was a 73 female with stage 3 MH (Fig 2). On day 1, the old method showed MH closed (Fig 3A), but the new method revealed MH open (Fig 3B). The additional 1 day posturing closed MH (Fig 3C). Three months after surgery, MH remained closed with visual acuity of 1.0 (Fig 4). The new technique to observe MH using gas-OCT is very useful for deciding post-operative protocol.

**Dr. Taiji Sakamoto, MD, PhD**  
Kagoshima University, Japan

### References

1. Masuyama K, et al. *Am J Ophthalmol* 2009;147:481-8.
2. Yamashita T, et al. *Ophthalmologica*. 2013;229:43-9




Fig 1a




Fig 1b




Fig 1c




Fig 2




Fig 2




Fig 3a




Fig 3b




Fig 3c




Fig 4



## Navigated laser photocoagulation system (NAVILAS)

**Dr. Jay Chhablani**

*Smt. Kanuri Santhamma Retina Vitreous Centre  
L.V.Prasad Eye Institute, \*Kallam Anji Reddy Campus,  
L.V.Prasad Marg, Banjara Hills, Hyderabad - 500 034  
Email: jaychhablani@hpei.org*

Gerd Meyer-Schwickerath introduced retinal photocoagulation therapy using the xenon arc photocoagulator during the 1950s, since then there has been a constant improvement in the laser wavelength and delivery systems.<sup>1</sup> Laser photocoagulation plays an important role in the treatment of many retinal conditions, such as diabetic retinopathy, vascular occlusions, retinal tears and other ocular diseases. Various randomized trials have evidently established its role in diabetic retinopathy, both macular edema as well as proliferative diabetic retinopathy.<sup>2-4</sup>

While using conventional slit lamp laser system for focal laser photocoagulation; treatments often rely on the physician's ability to translate the information from fluorescein angiography (FA) images and to superimpose these interpretations onto the live fundus view during laser treatment. Limited view of the fundus, inverted fundus image, use of contact lens and associated pain are the other common drawbacks of conventional slit lamp delivery systems.

Laser photocoagulation delivery system has advanced, with the introduction of pattern scanning laser system, PASCAL laser (Topcon Medical Laser Systems, Santa Clara, CA, USA). With PASCAL laser system multiple laser spots can be applied in various patterns with single foot pedal press.<sup>5</sup> This significantly improves patient comfort and reduces treatment duration. However, the limited slit view and inverted fundus view are still the limitations. Documentation with both conventional slit lamp and PASCAL laser is still the hand-made drawings with inherent deficiencies. Training through these systems involves supervision through monocular side viewing scope and hand-made drawings.

Navigated laser photocoagulation (NAVILAS, (OD-OS, Teltow, Germany), a new integrated laser system that combines color fundus photography, fluorescein angiography, and infra-red imaging with a target locked frequency-doubled solid-state laser (wavelength 532nm).<sup>6</sup>



*Figure 1*

This advanced system systematic laser treatment including 4 steps: imaging, planning, treatment delivery and documentation using a single device.

**1. Image acquisition:** As the first step, color fundus or infra-red images are acquired using mydriatic or non-mydriatic camera (30 or 50 degrees) while watching the live view on the computer screen. The images are of high-resolution because Navilas<sup>®</sup> system obtains real-time images with eye tracking at a rate of 25 images per second.

**2. Planning:** Navilas<sup>®</sup> system offers, "computer based planning" for laser photocoagulation. The clinician marks the "no treatment zone", desired targets such as focal laser for microaneurysm or grid for diffuse macular edema on the computer screen image using either a touch screen or the mouse. (Figure 1) Wide range of spot size from 50  $\mu$ m to 1000  $\mu$ m with a pulse duration ranging from 10

mSec to 1000mSec is available and which can be individualized for each laser spot. Accuracy of the navigated laser treatment has been reported to be 92% compared to 72% that of the conventional laser.<sup>6</sup> Planning on the computer screen by trainees can be easily supervised which makes Navilas<sup>®</sup> system an excellent teaching tool and ensures patient safety as well.

Any image obtained on other imaging systems such as indocyanine green angiogram or macular thickness map on spectral domain optical coherence tomography, autofluorescence can be easily imported on to Navilas<sup>®</sup> system to allow multimodal image integration for treatment planning.

3. **Treatment:** The treatment plan is then registered on to the live fundus image (infrared or color) of the retina, facilitating more precise positioning of laser spots. The clinician performs 532nm laser photocoagulation on the intended targets while watching the live video on the computer screen. Treatment is performed in infrared mode, which is more comfortable for the patient than the bright white slit lamp bright light. Treatment is performed on upright images, so it avoids any confusion as encountered in conventional laser treatment due to inverted image. The treatment does not require use of contact lens or topical anaesthesia, increasing comfort for both, clinician and patient.<sup>7</sup> Clinician can toggle between the color fundus view and infrared view to determine the intensity of each burn and adjust the power as necessary. In case of any sudden movement of the eye, the registration fails and the laser treatment stops immediately. The advantage of eye tracking during treatment makes Navilas<sup>®</sup> system a safe and time-efficient treatment.<sup>8,9</sup> The Navilas also automatically advances the aiming beam from the marked site to the next, after each photocoagulation spot until they are all treated. The precise placement of the laser allows lower total energy delivery, with the potential for less collateral damage.<sup>8</sup>



Figure 2

4. **Documentation:** At end of the treatment, Navilas<sup>®</sup> system provides digital documentation of the entire procedure including treatment plan, laser parameters, post-treatment color photo showing treated areas. This accurate information helps for follow up of subjects especially when repeat treatment is required. (Figure 2)

Panretinal photocoagulation with Navilas<sup>®</sup> system: Wide-angle contact lens for panretinal photocoagulation using Navilas<sup>®</sup> system provides a wider view almost up to ora serrata. (Figure 3) Navilas<sup>®</sup> system provides a uniform circular, equally intense and focused peripheral burns and faster PRP treatment compared to PASCAL. Use of navigated laser during panretinal photocoagulation improves the safety as well.




Figure 3

Limitations of Navilas<sup>®</sup> system: There are few limitations of NAVILAS including no stereoscopic view, unavailability of indocyanine green angiography (ICG)/optical coherence tomography (OCT). However, ICG and OCT images can be easily integrated into the Navilas<sup>®</sup> system for treatment planning.


In conclusion, Navilas<sup>®</sup> system provides use of multimodal imaging on a computer based treatment in a safe, efficient and accurate manner. It has several advantages over conventional laser systems such as improved patient/physician comfort, improved accuracy, excellent documentation and enhanced training. Navilas<sup>®</sup> system revolutionizes laser photocoagulation treatment and indicates the beginning of new era in vitreo-retinal disorders' management.

**Reference:**

1. Meyer-Schwickerath G. [Photo-coagulation of the ocular fundus and the retina]. *Ann Ocul (Paris)*. Jun 1956;189(6):533-548.
2. Diabetic Retinopathy Clinical Research N, Elman MJ, Qin H, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. *Ophthalmology*. Nov 2012;119(11):2312-2318.
3. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. *Ophthalmology*. Jul 1981;88(7):583-600.
4. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. *Ophthalmology*. Jul 1987;94(7):761-774.
5. Blumenkrantz MS, Yellachich D, Andersen DE, et al. Semiautomated patterned scanning laser for retinal photocoagulation. *Retina*. Mar 2006;26(3):370-376.
6. Kozak I, Oster SF, Cortes MA, et al. Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS. *Ophthalmology*. Jun 2011;118(6):1119-1124.
7. Kernt M, Cheuten RE, Cserhati S, et al. Pain and accuracy of focal laser treatment for diabetic macular edema using a retinal navigated laser (Navilas). *Clin Ophthalmol*. 2012;6:289-296.
8. Ober MD, Kernt M, Cortes MA, Kozak I. Time required for navigated macular laser photocoagulation treatment with the Navilas(R). *Graefes Arch Clin Exp Ophthalmol*. Aug 7 2012.
9. Kozak I, Kim JS, Oster SF, Chhablani J, Freeman WR. Focal navigated laser photocoagulation in retinovascular disease: clinical results in initial case series. *Retina*. May 2012;32(5):930-935.

## Eye Doctor ' Out of the box '

Fiction >> Science fiction >> General  
Fiction >> Themes >> Motifs >> Medical



By Ittyerah Tholath

Rating : Not yet rated.

Published : Jan 12, 2013

Words : 27,773 (approximate)

Language : English

ISBN : 9781301878284

### Short Description

A harmonious Fusion of Imagination with Knowledge aimed at eliminating old age sufferings and achieving youthful Life. Included in this is a brilliant 'Out of box' idea to tame cancer. A by-product of the implementation of this out of the box idea, could be an escape from death. Here is a better substitute for longevity and old age extension. The young age is extended and double by Binary fission.

Access : Smashwords.com Introductory price \$ 0.99.  
5% free download

*Review Article*

## TREATMENT OPTIONS FOR MYOPIC FOVEOSCHISIS - AN UPDATE

*Dr. Pramod Bhende \**

*Dr. Mobammad Arif Mulla\**

*\*SriBhagvanMahavir department of Vitreoretinal Surgery*

*Medical Research Foundation, Chennai, India.*

*email: drpb@snmail.org*

### ABSTRACT:

Myopic foveoschisis (MF) is one of the major causes of poor vision in highly myopic eyes over 40 years of age.

Its prevalence has been reported between 8% and 34%, in various studies. Pathogenesis of MF remains uncertain. Improved resolution and the quality of OCT imaging, helps not only in early diagnosis but has improved our ability to understand the patho-anatomic features of this condition

In recent years, various treatment modalities have been described in the literature for the treatment of MF. This review article aims to provide an overview and to summarize the current treatment options for MF.

**KEY WORDS:** Myopic Foveoschisis, optical coherence tomography (OCT), vitrectomy, Internal Limiting Membrane Peeling, Gas Tamponade

### INTRODUCTION:

The term myopic traction maculopathy was used first by Panozzo and Mercanti.<sup>1</sup> To describe a collection of pathologic changes associated with highly myopic eyes, including macular retinoschisis (MF), foveal detachment, and macular hole.

Myopic foveoschisis, also known as macular retinoschisis, or macular schisis, is defined as a separation of retinal layers. These changes are seen in 8% - 34% of eye with pathologic myopia and are more common in presence of posterior staphyloma.<sup>2-5</sup> MF predominantly involves outer retinal layers. If left untreated, more than 50% of eyes develop macular holes or posterior pole retinal detachment (RD) within two or more years of follow-up and eventually retinal destruction.

Before the advent of optical coherence tomography (OCT), this disorder was difficult to diagnose, and surgery typically was performed for presumed foveal detachment or macular hole. Takano and Kishi, in 1999, using OCT, first described this new entity, which they termed foveal retinoschisis.<sup>5</sup> As the resolution and the quality of OCT imaging has improved, so has our ability to understand the pathoanatomic features of this condition.

### PATHOPHYSIOLOGY:

As suggested by the name myopic traction maculopathy, it is widely accepted that a pulling or stretching force is the primary pathologic mechanism in this disorder. With increasing age, the height of staphyloma increases, leading to stretching and thinning of the posterior retina. The precise cause for this traction, however, is still debated. Few researchers reported several preretinal structures as the possible source of traction. However others believe that certain intrinsic elements are responsible for myopic traction maculopathy. Probably it is a combination of both.

The nontractional factors debated were, decreased pumping capacity of RPE and alterations of retinal cell adhesion properties. However these factors are questionable considering the excellent anatomical outcome in these eyes once traction is relieved.

Preretinal structures as possible source of traction are -

- Incomplete or partial posterior vitreous detachment (PVD) with vitreomacular adhesion
- Remnant cortical vitreous plaques after PVD
- Epiretinal membrane (ERM)



Preretinal structures are mainly responsible for antero-posterior traction with added tangential traction.<sup>1,2,4</sup>

Elements intrinsic to thinned myopic retina are -

- Taut internal limiting membrane (ILM)
- Shortened retinal arterioles

Either of the two could lead to tangential traction and various pathologic consequences<sup>6-9</sup> and eventually lead to partial or full thickness macular hole and staphyloma associated retinal detachment.

### TREATMENT:

The lack of consensus for a single pathophysiologic mechanism has resulted in a debate regarding the best approach for treatment in eyes with MF. Probably, vitrectomy with relief of antero-posterior and tangential traction is the most logical and accepted treatment modality.

The possible options available are-

1. Observation alone
2. Macular Buckling
3. Cataract extraction alone
4. Vitrectomy alone
5. Vitrectomy + ILM peeling
6. Vitrectomy + ILM peeling + Gas tamponade

#### 1. Observation:

The natural course and evolution of foveoschisis and the level of intraretinal cleavage is difficult to predict. It is also difficult to predict which patient will have a progressive course. MF may remain stable for many years without affecting vision.

In one study,<sup>10</sup> on OCT scans, of the 29 eyes, nine (31%) underwent little or no change in their foveoschisis profile over more than one year of follow-up and in two eyes, foveoschisis remained completely unchanged for more than four years.

Probably in eyes with stable and good vision, no obvious foveal traction and no progression of MF on OCT can be observed. Recording vision and serial OCT on every follow up visits will be useful in planning subsequent management in these eyes.

#### 2. Macular buckling:

Before the advent of vitrectomy, macular buckling and/or scleral re-inforcement were the only available option for the management of MF and macular hole with RD. Few researchers have reported reasonably good anatomical and functional outcome in these eyes following macular buckling. Extra ocular approach to the posteriorly located macular area and placement of buckle there is technically more challenging and has potential risk of complications.

With better understanding of pathoanatomy and availability of newer surgical techniques and refined instrumentation, vitrectomy (20, 23 or 25G) alone or in combinations with ILM peeling with/without internal tamponade have now become the treatment of choice leading to better visual outcomes but reducing the risk of complication associated with macular buckling alone.




Figure 1-Tractional ILM detachment (white arrow) with foveal schisis and retinal detachment.




Figure 2. - 48 years high myope with macular hole before (A) and after vitrectomy, ILM peeling and gas tamponade (B)

### 3. Cataract extraction alone:

In high myopic eyes, cataract appears at an earlier age and may progress more rapidly.<sup>11,12</sup> However, cataract extraction would increase the risk for posterior vitreous detachment, macular oedema, and retinal detachment, possibly due to disturbance to the vitreous body during surgery<sup>13-16</sup> or thereafter (endophthalmodiodesis)

Highly myopic eyes, even when combined with a macular condition such as MF, may require cataract extraction to improve vision and correct refraction.

One of the studies<sup>17</sup> has shown that, after cataract surgery, there was immediate improvement in the BCVA in patients with MF. The vision continued to improve over next 3 months. By 15 months, the vision got stabilized in most patients. Although the central foveal thickness increased after cataract extraction, authors reported that, in most patients the macular morphology remained fairly stable without emergent changes for 15 months.

This implies that clinicians can perform cataract extraction in eyes with MF and then manage the macular condition later, if necessary, depending on course of the foveoschisis

### 4. Vitrectomy alone:

SD OCT gives an opportunity for more detailed analysis of vitreo-macular interface and intra-retinal structures in eyes with MF, such as defects in the photoreceptor layer and presence of foveal detachment. The risk of worsening of vision increases when MF is associated with pre-macular structures such as ERM or a partially detached vitreous cortex and foveal detachment. Vitrectomy alone<sup>18</sup> may help in resolution of macular abnormalities without peeling the ILM in these eyes.

Status of the macula on SD-OCT should be taken into consideration, along with other relevant clinical information such as visual acuity and axial length, while deciding the timing of surgery for patients with MF. Photoreceptor layer defects and underlying irregular choroidal surface on the OCT may predict poor postoperative vision in these eyes despite successful surgery.

In eyes, with threatened disruption of the outer retina, presence of ERM and longer axial length, early surgery may prevent macular hole formation with overall good final anatomical and functional outcome.

### 5. Vitrectomy and internal limiting membrane (ILM) peeling:

The need for ILM peeling and gas tamponade is debatable

Instead of ILM peeling, surgeons have tried to remove adherent plaques of vitreous or indistinct vitreous sheets using various techniques. ILM peeling is probably not essential for the eyes with obvious preretinal traction. However, ILM peeling ensures complete removal of any possible tractional components, such as the overlying pre-macular vitreous cortex and fibroglial components on the surface of the ILM.

Wollensak et al<sup>31</sup> in their study, have reported that the biomechanical rigidity of the ILM increases with age and peeling of ILM increases retinal compliance by 53.6%. This reduced rigidity may help retina to conform better to the staphyloma<sup>20, 26, 27</sup> with resolution of MF.

Many studies demonstrated that vitrectomy with ILM peeling results in resolution of myopic foveoschisis and subsequent visual improvement in over 80% of patients within 6 months.<sup>19-22</sup>

Sayanagi and associates<sup>22</sup> reported 2 eyes, with persistent MF following primary vitrectomy without ILM peeling. These eyes were treated successfully by reoperation with complete removal of vitreous cortex and ILM peeling. These observations may support a beneficial role for ILM peeling in the eyes with MF.

Other investigators have demonstrated comparable results, both anatomical and functional, in groups with and without ILM peeling<sup>23-25</sup>

Investigators have<sup>1,2</sup> demonstrated that, in certain eyes, no preretinal structures can be identified before or during surgery. In such eyes, relative non-compliance of the inner retina is probably due to the highly elastic nature of ILM, making it relatively taut

and is responsible for resistant to permanent stretching of the retina to conform with deformed sclera within the staphyloma. Alternatively, it may be the result of microscopic cellular and collagen proliferation on the surface of the ILM that develops after PVD and may not be detectable clinically.<sup>28, 29</sup> In either case, peeling of the ILM ensures complete removal of both preretinal and intrinsic traction and thereby increasing chances of resolution of the maculopathy.<sup>6, 9, 22, 30</sup>

However, ILM peeling in highly myopic eyes can be challenging due to its consistency, lack of contrast due to atrophy of underlying retinal pigment epithelium and limited reach of instruments to macular area due to enlarged axial length. ILM peeling may itself be a risk factor for iatrogenic macular hole in highly myopic eyes because of pre-existing retinal thinning.

Based on the above observations, a surgeon has 2 options when approaching a patient with visually significant myopic traction maculopathy.

In eyes with obvious preretinal traction, removal of vitreomacular adhesion or ERM to resolve the major traction mechanism, leaving the ILM intact, may help in settling down the retina. This approach avoids the risk of operative complications associated with ILM peeling.<sup>25</sup>

Alternatively, a comprehensive approach to address all apparent preretinal traction elements including ILM peeling is likely to have the highest single surgery success rate. ILM peeling also ensures complete removal of preretinal tissues such as vitreous, cellular and collagen components that may contribute to current or future tangential traction.<sup>29</sup>

#### **6. Vitrectomy + ILM peeling + Gas tamponade:**

Gas tamponade may not always be necessary in the surgical treatment of MF, if the macular traction is released sufficiently, and in the absence of unexpected intraoperative events such as paravascular breaks or suspicious iatrogenic macular hole.

In a large retrospective case series of 24 highly myopic eyes with myopic traction maculopathy, Panozzo and Mercanti<sup>30</sup> demonstrated that, vitrectomy with ILM peeling led to a high rate of anatomic resolution (95.8%) and visual improvement, without the use of gas tamponade. However, the recovery process was very slow. (mean, 4.4 months; range, 1–12 months).

Few researchers have reported use of gas tamponade at the end of surgery to flatten the retina, whether ILM was peeled or not. Kumagai and associates<sup>28</sup> have studied various factors responsible for better functional outcome in eyes who underwent vitrectomy with ILM peeling for treatment of myopic foveoschisis. They reported that, with gas tamponade, there was a tendency for eyes to have a better visual outcome, however this was not statistically significant.

Kim KS et al, in their series<sup>32</sup> reported that the gas-treated group had more rapid resolution of MF (mean, 2.25 months; range, 1–3 months) when compared to the no-gas group. In no-gas group, one eye took 8 months for MF resolution. (mean 4.50 months; range, 2–8 months). In addition, at 1 month after surgery, the mean central foveal thickness (CFT) of the gas-treated group was lower than that of the no-gas group, although the difference was not statistically significant (P .059).

Gas can induce pneumatic displacement of outer-layer detachment leading to quicker repositioning. Nevertheless, the mechanical effect of a gas tamponade may be insufficient for complete repositioning of the retinal layers, as gas gets reabsorbed within 1 to 2 months, whereas complete resolution of retinoschisis, in some eyes, may not be achieved until that time.

Hirakata and Hida<sup>33</sup> suggested that intravitreal gas may push the sub-retinal fluid inside the limited space under the foveal detachment and can lead to post surgery macular hole formation.

#### **CONCLUSION:**

MF is seen commonly in high myope with posterior staphyloma. SD OCT is a useful tool for diagnosis. If left untreated it may lead to permanent and significant visual loss. Early detection and treatment may help in better anatomical and functional outcome. The lack of consensus for a single pathophysiologic mechanism has led to multiple approaches for treatment for MF. Herein, we reviewed the possible mechanisms responsible for myopic tractional maculopathy. Though vitrectomy is most accepted treatment modality, the surgery can be tailored to the specific pathologic mechanism involved in a given eye for final successful outcome.

**REFERENCES:**

1. Panozzo G, Mercanti A. Optical coherence tomography findings in myopic traction maculopathy. *Arch Ophthalmol* 2004;122:1455-1460.
2. Wu PC, Chen YJ, Chen YH, et al. Factors associated with foveoschisis and foveal detachment without macular hole in high myopia. *Eye* 2009;23:356-361.
3. Baba T, Obno-Matsui K, Futagami S, et al. Prevalence and characteristics of foveal retinal detachment without macular hole in high myopia. *Am J Ophthalmol* 2003;135:338-342.
4. Fang X, Weng Y, Xu S. Optical coherence tomographic characteristics and surgical outcome of eyes with myopic foveoschisis. *Eye* 2009; 23:1336-1342.
5. Takano M, Kishi S. Fovealretinoschisis and retinal detachment in severely myopic eyes with posterior staphyloma. *Am J Ophthalmol* 1999;128:472-476.
6. Sayanagi K, Ikuno Y, Tano Y. Tractionalinternallimitingmembrane detachment in highly myopic eyes. *Am J Ophthalmol* 2006;142:850-852.
7. Ikuno Y, Gomi F, Tano Y. Potentretinalarteriolartractionas a possible cause of myopic foveoschisis. *Am J Ophthalmol* 2005;139:462-467.
8. Sayanagi K, Ikuno Y, Gomi F, Tano Y. Retinal vascular microfolds in highly myopic eyes. *Am J Ophthalmol* 2005; 139:658-663.
9. Ikuno Y, Sayanagi K, Soga K, et al. Foveal anatomical status and surgical results in vitrectomy formyopic foveoschisis. *Jpn J Ophthalmol* 2008;52:269-276.
10. GaucherD, HaouchineB, TadayoniR. Long-term follow-up of high myopic foveoschisis: Natural course and surgical outcome. *Am J Ophthalmol* 2007;143:455-462.
11. Xu L, Li J, Cui T, Hu A, et al. Refractive error in urban and rural adult Chinese inBeijing. *Ophthalmology* 2005; 112:1676-1683.
12. Younan C, Mitchell P, Cumming RG, et al. Myopia and incident cataract and cataract surgery: The BlueMountains Eye Study. *Invest Ophthalmol Vis Sci* 2002;43:3625-3632.
13. Lim R, Mitchell P, Cumming RG. Refractive associations withcataract: The Blue Mountains Eye Study. *Invest OphthalmolVisSci* 1999; 40:3021-3026.
14. Neal RE, Bettelheim EA, Lin C, et al. Alterations in human vitreous humour followingcataract extraction. *Exp Eye Res* 2005; 80:337-347.
15. Ripandelli G, Scassa C, Parisi V, et al. Cataract surgery as a risk factor for retinal detachmentin very highly myopic eyes. *Ophthalmology* 2003; 110:2355-2361.
16. Ripandelli G, Coppe' AM, Parisi V, et al. Posterior vitreous detachment and retinal detachment after cataract surgery. *Ophthalmology* 2007;114:692-697.
17. Ripandelli G, Billi B, Fedeli R, Stirpe M. Retinal detachment afterclear lens extraction in 41 eyes with high axial myopia. *Retina*1996; 16:3-6.
18. LaiCC, YeungL, ChenYP, et al. Macular and visual outcomes after cataractextraction for highly myopic foveoschisis. *J Cataract Refract Surg* 2008; 34:1152-1156.
19. Shin JY, YuHG. Visualprognosis and spectral-domain Optical Coherence Tomography findings of myopic foveoschisis surgery using 25-Gauge transconjunctivalsuturelessvitrectomy. *Retina*32:486-492, 2012.
20. Kobayashi H, Kishi S. Vitreous surgery for highly myopic eyes with foveal detachment and retinoschisis. *Ophthalmology* 2003;110:1702-1707.
21. Kanda S, Uemura A, Sakamoto Y, Kita H. Vitrectomy with internal limiting membrane peeling for macular retinoschisis and retinal detachment without macular hole in highly myopic eyes. *Am J Ophthalmol* 2003;136:177-180.
22. Ikuno Y, Sayanagi K, Ohji M, et al. Vitrectomy and internal limiting membrane peeling for myopic foveoschisis. *Am J Ophthalmol* 2004;137:719-724.
23. Sayanagi K, Ikuno Y, Tano Y. Reoperation for persistentmyopic foveoschisis after primary vitrectomy. *Am J Ophthalmol* 2006;141:414-417.
24. Kwok AK, Lai TY, Yip WW. Vitrectomy and gas tamponade without internal limiting membrane peeling for myopicfoveoschisis. *Br J Ophthalmol* 2005;89:1180-1183.
25. Spaide RF, Fisher Y. Removal of adherent cortical vitreous plaques without removing the internal limiting membrane in the repair of macular detachments in highly myopic eyes. *Retina* 2005;25:290-295.
26. Yeh SI, Chang WC, Chen LJ. Vitrectomy without internal limiting membrane peeling for macular retinoschisis and foveal detachment in highly myopic eyes. *ActaOphthalmol*2008;86:219-224.
27. Kubn F. Internal limiting membrane removal for macular detachment in highly myopic eyes. *Am J Ophthalmol* 2003; 135:547-549.
28. Kumagai K, Furukawa M, Ogino N, Larson E. Factors correlated with postoperative visual acuity after vitrectomy and internal limiting membrane peeling for myopic foveoschisis. *Retina* 2010;30:874-880.
29. Bando H, Ikuno Y, Choi JS, et al. Ultrastructure of internal limiting membrane in myopic foveoschisis. *Am J Ophthalmol* 2005;139:197-199.
30. Panozzo G, Mercanti A. Vitrectomy for myopic traction maculopathy. *Arch Ophthalmol* 2007;125:767-772.
31. Wollensak G, Spoerl E, Grosse G, Wirbelauer C. Biomechanicalsignificance of the human internal limiting lamina. *Retina* 2006;26:965-968.
32. Kim KS, Lee SB, Lee WK et al. Vitrectomy and internal limiting membrane peeling with and without gas tamponade for myopic foveoschisis. *Am J Ophthalmol* 2012;153:320-326.
33. Hirakata A, Hida T. Vitrectomy for myopic posterior retinoschisis or foveal detachment. *Jpn J Ophthalmol* 2006;50:53-61.



**EVERY  
LINE OF  
VISION  
GAINED IS A PIECE OF LIFE RESTORED**

**THE WORLD IS BEAUTIFUL > TO LOOK AT**

**Only Anti VEGF now approved for:**

**Age-Related  
Macular  
Degeneration**

**Diabetic  
Macular Edema\***

**Retinal  
Vein Occlusion\***

\*For Management of Visual Impairment Secondary to the Macular Edema

**Basic Succinct Statement:** LUCENTIS® Presentation: Ranibizumab. Each vial contains 2.3 mg of ranibizumab in 0.23 mL solution. **Indications:** Treatment of neovascular (wet) age-related macular degeneration (AMD). • Treatment of visual impairment due to diabetic macular edema (DME). • Treatment of visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or central RVO). **Dosage:** • The recommended dose is 0.5 mg (0.05 mL) given as a single intravitreal injection. The interval between two doses should not be shorter than 1 month. • Patients should be monitored monthly for visual acuity. Treatment is given monthly and continued until maximum visual acuity is achieved, confirmed by stable visual acuity for three consecutive monthly assessments performed while on Lucentis® treatment. • Treatment is resumed with monthly injections when monitoring indicates a loss of visual acuity due to wet AMD, DME or macular edema secondary to RVO and continued until stable visual acuity is reached again for three consecutive monthly assessments. • Lucentis and laser photocoagulation in DME or in branch RVO: Lucentis has been used concomitantly with laser photocoagulation in clinical studies. When given on the same day, Lucentis should be administered at least 30 minutes after laser photocoagulation. Lucentis can be administered in patients who have received previous laser photocoagulation. • Lucentis must be administered by a qualified ophthalmologist using aseptic techniques. Broad-spectrum topical microbicide and anaesthetic should be administered prior to the injection. • The patient should be instructed to self-administer antimicrobial drops four times daily for 3 days before and after each injection. • Not recommended in children and adolescents. **Contraindications:** Hypersensitivity to ranibizumab or to any of the excipients, patients with active or suspected ocular or periocular infections, patients with active intraocular inflammation. **Precautions/Warnings:** • Intravitreal injections have been associated with endophthalmitis, intraocular inflammation, rhegmatogenous retinal detachment, retinal tear and iatrogenic traumatic cataract. Therefore proper aseptic injection techniques must be used. Patients should be monitored during the week following the injection to permit early treatment if an infection occurs. • Transient increases in intraocular pressure (IOP) have been seen within 60 minutes of injection of Lucentis. Sustained IOP increases have also been reported. Intraocular pressure and the perfusion of the optic nerve head must be monitored and managed appropriately. • There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors. A numerically higher stroke rate was observed in patients treated with ranibizumab 0.5 mg compared to ranibizumab 0.3 mg or control, however, the differences were not statistically significant. Patients with known risk factors for stroke, including history of prior stroke or transient ischemic attack should be carefully evaluated by their physicians as to whether Lucentis treatment is appropriate and the benefit outweighs the potential risk. • As with all therapeutic proteins, there is a potential for immunogenicity with Lucentis. • Lucentis has not been studied in patients with active systemic infections or in patients with concurrent eye conditions such as retinal detachment or macular hole. • There is limited experience with treatment of patients with prior episodes of RVO and of patients with ischemic branch RVO (BRVO) and central RVO (CRVO). In patients with RVO presenting with clinical signs of irreversible ischemic visual function loss, treatment is not recommended. • Should not be used during pregnancy unless the expected benefit outweighs the potential risk to the fetus. For women who wish to become pregnant and have been treated with ranibizumab, it is recommended to wait at least 3 months after the last dose of ranibizumab before conceiving a child; use of effective contraception recommended for women of child-bearing potential; breast-feeding not recommended. • Following treatment patients may develop transient visual disturbances that may interfere with their ability to drive or use machines. Patients should not drive or use machines as long as these symptoms persist. **Interactions:** No formal interaction studies have been performed. **Adverse reactions:** • **Very common adverse reactions** are: intraocular inflammation, vitritis, vitreous detachment, retinal hemorrhage, visual disturbance, eye pain, vitreous floaters, conjunctival hemorrhage, eye irritation, foreign body sensation in eyes, lacrimation increased, blepharitis, dry eye, ocular hyperemia, eye pruritus, intraocular pressure increased, nasopharyngitis, headache, arthralgia. • **Common adverse reactions** are: retinal degeneration, retinal disorder, retinal detachment, retinal tear, detachment of the retinal pigment epithelium, retinal pigment epithelium tear, visual acuity reduced, vitreous hemorrhage, vitreous disorder, uveitis, iritis, iridocyclitis, cataract, cataract subcapsular, posterior capsule opacification, punctate keratitis, corneal abrasion, anterior chamber flare, vision blurred, injection site hemorrhage, eye hemorrhage, conjunctivitis, conjunctivitis allergic, eye discharge, photopsia, photophobia, ocular discomfort, eyelid edema, eyelid pain, conjunctival hyperemia, stroke, influenza, urinary tract infection\*, anemia, anxiety, cough, nausea, allergic reactions (rash, pruritus, urticaria, erythema). **Uncommon** • **adversereactions** are: blindness, endophthalmitis, hypopyon, hyphema, keratopathy, iris adhesions, corneal deposits, corneal edema, corneal striae, injection site pain, injection site irritation, abnormal sensation in eye, eyelid irritation. • **Serious adverse events** related to intravitreal injections included endophthalmitis, rhegmatogenous retinal detachment, retinal tear and iatrogenic traumatic cataract. • **observed only in the DME population** Packs: Pack of 1 vial Before prescribing, please consult full prescribing information available from Novartis Healthcare Private Limited, Sandoz House, Dr. Annie Besant Road, Worli, Mumbai - 400 018, Tel: 022 2495 8888 For the use only of a registered medical practitioner or a hospital or a laboratory only. India BSS dated 21 July 2011 based on international BSS dtd 10 June 2011.



Full product information available from:  
Novartis Healthcare Pvt. Ltd.  
Sandoz House, 6th floor, Dr. Annie Besant Road, Worli, Mumbai - 400 018 India.  
Tel: +9122 24976890 Fax: +9122 24970362

**LUCENTIS®**  
RANIBIZUMAB  
Improving vision. Restoring hope.

# XXI<sup>st</sup>



## Vitreo Retina Society-India Annual Meet

The 21st annual conference of VRSI-I was held at the International Convention Center, Srimanta Sankaradeva Kalakshetra, Guwahati on December 6th -8th, 2012. The conference venue chosen was one of the most attractive places of tourist interest in the city. Guwahati, the ancient city of 'Pragjyotishpur', is today the gateway of Northeast India. The conference was organized by Sri Sankaradeva Nethralaya under the aegis of Ophthalmological Society of Assam (OSA).

It was for the first time VRSI meeting held in the North-Eastern part of India and it was a great success.

A large numbers of delegates from all over the country attended the extraordinary academic feast.



Renowned international faculties like Prof Jayakrishna Ambati, Prof Taiji Sakomoto, and Dr Raj Apte attended the meeting this time. Prof Jayakrishna Ambati, known for his pioneering work on age related macular degeneration, delivered 'Nataraja Pillai oration' this year. Dr Taraprasad Das delivered the 'Hayreh Award lecture' this year. A unique feature of this year's scientific program was that, the free papers formed the part and parcel of the main conference sessions instead of being presented as 'free paper' sessions. All the sessions were well attended and discussed by the delegates and active participation of the young doctors was encouraging.

The trade exhibition was very attractive with spacious and decorative arena that was participated by good numbers of companies and also new equipments in the field of vitreoretina were demonstrated.





A very special spouse & children program was designed in the beautiful venue which was really enjoyable.

The best part of the VRSI 2012 was the complimentary Pobitora Wild Life Sanctuary (famous for its one-horned rhinoceros) trip for the delegates which must have been a life time experience.

An extraordinary cultural event blended with excellent traditional hospitality must have impressed the delegates to remember VRSI2012 forever.



# XXIInd Annual Meet Vitreo Retina Society of India

**12th - 14th December, 2013**

Organized by :  
The Retina Conglomerate



Under the Aegis of



[www.vrsi2013.com](http://www.vrsi2013.com)

Venue : Lavasa





## SCIENTIFIC HIGHLIGHTS

### Nataraja Pillai Oration

Dr. Alan Bird, Emeritus Professor of Medical Ophthalmology, Honorary Consultant Moorfields Eye Hospital, U. K.

### Dr. B. Patnaik Oration

Dr. Rajvardhan Azad, Professor & Chief of Ophthalmology, All India Institute of Ophthalmology, New Delhi.

More international speakers are invited and their names will be announced in next communication



Contact details :

### Dr. V. Narendran

Scientific Committee Convener,  
Aravind Eye Hospital & Post Graduate Institute  
of Ophthalmology, Avinashi Road,  
Coimbatore - 641014.

Email: vrsiscicom@gmail.com

### Governing Council

#### President

Dr. Mangat R Dogra

#### Vice President

Dr. Ajit Babu Majji

#### Honorary Secretary

Dr. A. Giridhar

#### Joint Secretary

Dr. Raja Narayanan

#### Convener - Scientific Committee

Dr. V. Narendran

#### Treasurer

Dr. Ajay Aurora

#### Jt. Treasure

Dr. Saurabh Luthra

#### Local Organising Committee

#### Chairman

Dr P N Nagpal  
Prof S Natarajan  
Dr S B Kelkar

#### Secretary

Dr Aditya Kelkar

#### Joint Secretary

Dr Manish Nagpal  
Dr Alokpratap Singh



I  
N  
V  
I  
T  
A  
T  
I  
O  
N

# XXIInd Annual Meet INVITATION Vitreo Retina Society of India

Dear Colleagues,

The Organising Committee takes great pleasure in inviting you for the 22nd ANNUAL VITREO RETINA SOCIETY OF INDIA MEET, to be held from 12th - 14th Dec. 2013, at the International Convention Centre, Lavasa. This meeting is being organized by the Retina Conglomerate, under the aegis of the Maharashtra Ophthalmology Society and the Pune Ophthalmology Society.

Over the years the field of ophthalmology has grown and specialized research in various areas has been done. Today it has become a necessity to keep updated with the latest trends and changing technologies. The scientific program is being designed with a focus on content and quality deliberations.

The conference is being held at a beautiful location, Lavasa, near the Mulshi lake and dam. Lavasa is India's first and largest new hill city based on the principles of new urbanism & an eco friendly township. It is nested amidst the majesty of the Sahyadri Mountains along 60 km contours of the Warasgaon Lake. **It is a 45 minute drive from Pune and around 3 hour drive from Mumbai.** A self contained world, Lavasa offers its visitors and residents a spectacular array of business, educational recreational and rejuvenation opportunities so that you can live life in full. Come and experience it for yourself.

**Dr Aditya Kelkar**  
Organizing Secretary

# *D*expand your thinking



The 1st approved pharmacotherapy for  
macular edema following BRVO and CRVO\*

**Ozurdex**<sup>®</sup>  
(dexamethasone intravitreal  
implant) 0.7 mg

DESIGNED TO DELIVER

\*OZURDEX<sup>®</sup>, Summary of Product Characteristics.



Allergan India Pvt. Ltd., Level 2, Prestige Obelisk, No.3, Kasturba Road, Bangalore - 560 001 Tel: 91-80-4070 7070 Email: [allergan@agnindia.com](mailto:allergan@agnindia.com)

IN/0077/2010

# Game Changer

In 1968, Dick Fosbury revolutionized the high jump by developing a technique that elevated him to Olympic gold, raising the bar for athletes the world over.



## It's time to rewrite the rules of vitreoretinal surgery.

- Experience the ULTRAVIT® 5000 cpm probe with surgeon-controlled duty cycle to **reduce iatrogenic tears and post-op complications**<sup>1</sup>
- Trust in integrated and **stable IOP compensation**<sup>2</sup>
- **Enhance patient outcomes** and achieve faster visual recovery with ALCON® MIVS platforms<sup>3</sup>
- **Improve your OR turnover by 39%** with V-LOCITY® Efficiency Components<sup>4</sup>



# Alcon®

a Novartis company



## constellation

VISION SYSTEM

Welcome to the new possible.

© 2011 Novartis 9/11 CON11241JAD [AlconRetina.com](http://AlconRetina.com)

1. Rizzo S, et al. Comparative Study of the Standard 25-gauge Vitrectomy System vs the New Ultra-high-speed Vitrectomy System. *Retina Today*, September Insert, 2010. 2. Data on File, Alcon Research 954-2020-003. 3. Nagpal M, Wankar S, Nagpal K. Comparison of clinical outcomes and wound dynamics of sclerotomy ports of 20, 25, and 23 gauge vitrectomy. *Retina*. 2009;29(2):225-231. 4. Alcon data on file 954-0000-004.

**Indications for Use:** The CONSTELLATION® Vision System is an ophthalmic microsurgical system that is indicated for both anterior segment (i.e., phacoemulsification and removal of cataracts) and posterior segment (i.e., vitreoretinal) ophthalmic surgery. **Caution:** Federal (USA) law restricts this device to sale by, or on the order of, a physician. **Warnings and Precautions:** The disposables used in conjunction with Alcon instrument products constitute a complete surgical system. Use of disposables and handpieces other than those manufactured by Alcon may affect system performance and create potential hazards. Attach only Alcon supplied consumables to console and cassette luer fittings. Do not connect consumables to the patient's intravenous connections. Mismatch of consumable components and use of settings not specifically adjusted for a particular combination of consumable components may create a patient hazard. Vitreous traction has been known to create retinal tears and retinal detachments. The closed loop system of the CONSTELLATION® Vision System that adjusts IOP cannot replace the standard of care in judging IOP intraoperatively. If the surgeon believes that the IOP is not responding to the system settings and is dangerously high, this may represent a system failure. **Note:** To ensure proper IOP Compensation calibration, place infusion tubing and infusion cannula on a sterile draped tray at mid-cassette level during the priming cycle. Leaking sclerotomy may lead to post operative hypotony. **Important Safety Information: Warnings and Cautions:** A complete listing is available in the CONSTELLATION® Vision System Operators Manual. To obtain a copy, please contact Alcon Customer Service. **Attention:** Reference the Directions for Use for a complete listing of indications, warnings, and precautions.